Treatment for Retinal Vein Occlusion at South Carolina Retina Institute

Treatment For Retinal Vein Occlusion At South Carolina Retina Institute

South Carolina Retina Institute (SCRI) can offer patients the latest advancement in the treatment of retinal vein occlusion (RVO) – the FDA-approved Genentech’s VABYSMO® (faricimab-svoa). On October 26, 2023, Genentech announced the approval of VABYSMO® for RVO, marking its third ophthalmic indication as a bispecific antibody. Originally designed to address two causes of wet age-related macular degeneration (AMD) and diabetic macular edema (DME), VABYSMO® has now proven to be a groundbreaking therapeutic injectable for retinal vein occlusion.

Understanding Retinal Vein Occlusion (RVO)

Retinal vein occlusion occurs when the retinal veins, responsible for carrying blood away from the retina, become blocked. This blockage leads to increased pressure in the blood vessels, causing damage to the retina and resulting in vision loss. VABYSMO® is the first and only treatment specifically designed to block both types of proteins involved in abnormal blood vessel swelling, leaking fluid, and blood vessel growth – making it a crucial therapeutic option for macular edema following RVO.

There are two primary types of RVO – central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO). CRVO involves the blockage of the main retinal vein, while BRVO affects a smaller branch. CRVO is generally more severe, potentially leading to significant vision loss compared to BRVO.

RVO Treatment

VABYSMO® is a bispecific antibody that targets the underlying causes of RVO, offering a comprehensive approach to reducing abnormal blood vessel swelling, fluid leakage, and blood vessel growth. This medication brings hope for patients dealing with the consequences of RVO, providing an effective means to address macular edema associated with this condition.

Importance of Early Recognition and Treatment

To safeguard your vision, it is crucial to recognize and treat RVO promptly. The severity, location of the occlusion, and its complications determine the appropriate course of treatment. Macular edema, abnormal blood vessel growth, vitreous hemorrhage, or glaucoma may result from RVO. Intravitreal medications and laser therapy are common approaches to reduce swelling, promote blood flow, and restore vision.

Before initiating treatment, it is essential to provide your healthcare provider with a comprehensive overview of your medical history and current medications. Your overall health and the severity of your eye condition will be thoroughly assessed to tailor a personalized treatment plan that suits your individual needs. The experienced retina specialists at SCRI are dedicated to working closely with you to ensure the best possible care and outcomes.

Skilled Vitreoretinal Surgeons, Dr. Nicolas Marchese and Dr. Jorge Jiménez, are board-certified in treating diseases and performing surgery on the vitreous and retina. Our medical practices located in Murrells Inlet and Conway are dedicated to helping individuals throughout Myrtle Beach and the Grand Strand to preserve their vision.

At South Carolina Retina Institute, our commitment to providing top-notch care for our patients drives us to stay informed about the latest medical breakthroughs. Genentech’s VABYSMO® represents a significant breakthrough in the treatment of retinal vein occlusion, offering hope and effective solutions for individuals facing this challenging condition. If you or a loved one is dealing with RVO, contact SCRI today for a consultation, and let our team of dedicated professionals guide you towards preserving or improving your eyesight.